Stay updated on Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial

Sign up to get notified when there's something new on the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Added Melanoma as a topic label, added related topic 'MedlinePlus Genetics', and updated page revision from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-14T03:29:29.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Removed the Melanoma topic and the MedlinePlus Genetics related topic from the Study Details page.
    Difference
    0.2%
    Check dated 2026-01-07T01:46:07.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    Locations section updated to include Kentucky, Pennsylvania, and Texas, with the page revision updated to v3.3.3.
    Difference
    0.5%
    Check dated 2025-12-23T21:16:52.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Added Melanoma and MedlinePlus Genetics as related topics on the study page. These additions serve as metadata for context and indexing.
    Difference
    0.2%
    Check dated 2025-12-02T14:01:22.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added and Revision: v3.2.0 was removed in the page header, a minor versioning update that does not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T10:10:29.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page deleted the government funding notice and operating status details and removed related topic links (Melanoma; MedlinePlus Genetics). Core study content including title, condition, pembrolizumab intervention, study design, eligibility criteria, and outcomes remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.6%
    Check dated 2025-11-18T03:28:19.000Z thumbnail image

Stay in the know with updates to Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neoadjuvant PD-1 Blockade in Stage IIB/C Melanoma Clinical Trial page.